Selumetinib is a potent and highly selective reversible MEK inhibitor (MEK-I), currently approved in combination with vemurafenib, a BRAF-inhibitor (BRAF-I), for advanced BRAF-mutated melanoma patients. This evidence concerns the gene MAP2K7 and melanoma.